Picture of Achilles Therapeutics logo

ACHL — Achilles Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m+3.67%
3m-18.43%
6m-40.77%
1yr-80.12%
Volume Change (%)
10d/3m-57.25%
Price vs... (%)
52w High-81.15%
50d MA-6.2%
200d MA-47.33%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-21.54%
Return on Equity-25.52%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Achilles Therapeutics EPS forecast chart

Profile Summary

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    December 31st, 2021
    Incorporated
    November 18th, 2020
    Public Since
    March 31st, 2021
    No. of Employees
    242
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    40,754,227

    ACHL Share Price Performance

    Latest News for ACHL

    Upcoming Events for ACHL

    Achilles Therapeutics PLC Annual Shareholders Meeting

    Q2 2022 Achilles Therapeutics PLC Earnings Release

    Q3 2022 Achilles Therapeutics PLC Earnings Release

    Similar to ACHL

    Picture of 2Seventy Bio logo

    2Seventy Bio

    us flag iconNASDAQ Global Select Market

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of ACADIA Pharmaceuticals logo

    ACADIA Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    FAQ

    Or unlock with your email

    Or unlock with your email